v3.26.3
Segment Information - Summary of Segment Expenses and Reported Segment Net Loss (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Revenue from customers $ 2,830     $ 741     $ 5,660 $ 2,017
Revenue from licensing agreements 39     0     27,817 0
Early-stage research and development [1] (791)     (798)     (1,936) (2,328)
Late-stage research and development [2] (18,101)     (23,139)     (64,358) (50,087)
General and Administrative (5,867)     (5,165)     (17,892) (15,773)
Total operating expenses (24,759)     (29,102)     (84,186) (68,188)
Interest and other income, net 169     1,085     1,201 3,172
Change in fair value of 2023 Common Warrants 187     (4,205)     6,558 58,971
Loss before income tax (21,534)     (31,481)     (42,950) (4,028)
Income tax provision (326)     (56)     (3,454) (284)
Net loss $ (21,860) $ (1,504) $ (23,040) $ (31,537) $ (15,863) $ 43,088 $ (46,404) $ (4,312)
[1]

(1) Early-stage research and development includes costs incurred from Discovery programs.

[2]

(2) Late-stage research and development includes costs incurred from Phase 1 and Phase 2 clinical trial programs.